/

Merck & Co., Inc.

MRK US

MRK USMerck & Co., Inc.

United States Composite

126.88

USD

-0.06

(-0.05%)

0.14EPS Dil.

881.90P/E

321.21BMarket Cap

2.31%Div. Yield

Next Earnings

April 25

Ex-Dividend Date

March 14

Dividend Date

April 5

Held by Insiders

0.07%

Held by Institutions

78.62%

Short % of Float

0.66%

YTD Yield

9.49%

3Y Yield

70.94%

5Y Yield

78.14%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

2,839

887

1,372

LT Borrowings

34,072

33,972

33,683

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

2,539

2,535

2,532

Market Capitalization

293,024

261,009

275,999

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

29,977

31,954

32,168

Cash, Cash Equivalents & STI

6,378

8,773

7,093

Accounts Receivable, Net

11,030

10,394

10,349

Inventories

5,930

6,131

6,358

Total Current Liabilities

23,394

23,094

25,694

Payables & Accruals

20,555

22,207

24,322

ST Debt

2,839

887

1,372

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

3.55%

7.81%

1.40%

Net Income, GAAP

24.55%

5.69%

-97.49%

Free Cash Flow

15.85%

11.87%

-37.83%

Total Cash Common Dividend

3.59%

7.57%

6.18%

Total Equity

-1.43%

9.42%

-18.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

10,627

11,402

13,154

13,521

48,704

2022

15,901

14,593

14,959

13,830

59,283

2023

14,487

15,035

15,962

14,630

60,115

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

1.26

0.61

1.81

1.49

5.16

2022

1.70

1.56

1.28

1.19

5.73

2023

1.11

-2.35

1.87

-0.48

0.14

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

0.65

0.66

0.65

2.61

2022

0.69

0.70

0.69

2.77

2023

0.73

0.74

0.73

2.93

Company Description

CEO: Mr. Robert M. Davis J.D.
Full Time Employees: 70,000
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: 126 East Lincoln Avenue Rahway NJ United States 07065
IPO Date: Jan 2, 1962
CIK: 0000310158
Website: www.merck.com
Business: Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Company News

Yahoo
21 days ago
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Reuters
22 days ago
US takes next step in Medicare drug price negotiations with pharma companies
Reuters
22 days ago
Profitability is next sacrifice at inflation altar
Zacks
23 days ago
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Yahoo
23 days ago
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Yahoo
23 days ago
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Yahoo
a month ago
Merck & Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 98% Above Its Share Price
Zacks
a month ago
Merck (MRK) Rises Higher Than Market: Key Facts
Yahoo
a month ago
Merck (MRK) Rises Higher Than Market: Key Facts
Zacks
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Zacks
a month ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
Zacks
a month ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Yahoo
a month ago
Company News for Mar 28, 2024
Zacks
a month ago
Company News for Mar 28, 2024
Yahoo
a month ago
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Reuters
a month ago
POINT MARCHÉS Records en vue en Europe pour la dernière séance du trimestre
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Merck & Company (MRK)
Yahoo
a month ago
US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight

Company Description

CEO: Mr. Robert M. Davis J.D.
Full Time Employees: 70,000
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: 126 East Lincoln Avenue Rahway NJ United States 07065
IPO Date: Jan 2, 1962
CIK: 0000310158
Website: www.merck.com
Business: Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Company News

Yahoo
21 days ago
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Reuters
22 days ago
US takes next step in Medicare drug price negotiations with pharma companies
Reuters
22 days ago
Profitability is next sacrifice at inflation altar
Zacks
23 days ago
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Yahoo
23 days ago
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Yahoo
23 days ago
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Yahoo
a month ago
Merck & Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 98% Above Its Share Price
Zacks
a month ago
Merck (MRK) Rises Higher Than Market: Key Facts
Yahoo
a month ago
Merck (MRK) Rises Higher Than Market: Key Facts
Zacks
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Zacks
a month ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
Zacks
a month ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Yahoo
a month ago
Company News for Mar 28, 2024
Zacks
a month ago
Company News for Mar 28, 2024
Yahoo
a month ago
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Reuters
a month ago
POINT MARCHÉS Records en vue en Europe pour la dernière séance du trimestre
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Merck & Company (MRK)
Yahoo
a month ago
US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight